Related coverage linked through entity extraction aliases.
Mar 16, 2026
Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.
Mar 16, 2026
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
Mar 14, 2026
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
Mar 09, 2026
Pfizer's tilrekimig met its primary endpoint in a mid-stage eczema trial and will advance to late-stage testing. Separately, oral remibrutinib demonstrated rapid efficacy in treating peanut allergy in a phase II study.
Mar 09, 2026
The FDA has approved topical difamilast, a PDE4 inhibitor, for treating mild-to-moderate atopic dermatitis in adults and children aged 2 years or older, marking the third PDE4 inhibitor approval for this indication.
Mar 02, 2026
Regeneron has consistently increased revenue over 35 years with blockbuster products like Dupixent and Eylea HD, while maintaining over a dozen phase 3 clinical trial candidates across multiple therapeutic areas.
Feb 23, 2026
Merck and Mayo Clinic announced a research collaboration allowing Merck to use AI and advanced analytics with Mayo's clinical and genomic datasets for drug discovery, initially focusing on dermatology, neurology, and gastroenterology.
Feb 18, 2026
Alphyn Biologics has dosed the first patients in a Phase 2 trial of Zabalafin Hydrogel for Molluscum Contagiosum, enrolling 54 patients ages 6 months and older in a placebo-controlled study targeting 75% lesion elimination.
Feb 18, 2026
Merck announced a strategic collaboration with Mayo Clinic to leverage AI and advanced analytics in drug discovery, focusing initially on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Feb 18, 2026
Merck and Mayo Clinic announced a research agreement on February 18, 2026, to integrate AI and advanced analytics into drug discovery, initially targeting inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Feb 18, 2026
Merck and Mayo Clinic announced a research and development agreement to apply artificial intelligence and multimodal clinical data to support drug discovery and development, marking Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company.
Feb 18, 2026
Merck and Mayo Clinic announced a research and development agreement to apply artificial intelligence, advanced analytics and multimodal clinical data to support drug discovery and development, marking Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company.
Feb 18, 2026
Merck and Mayo Clinic announced a research and development agreement to leverage artificial intelligence, advanced analytics, and clinical-genomic data for drug discovery and precision medicine, initially focusing on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Feb 14, 2026
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
Feb 13, 2026
Researchers at Icahn School of Medicine at Mount Sinai found that major depressive disorder shares key immune abnormalities with atopic dermatitis, particularly Th2 pathway activation. The team plans to test dupilumab in a clinical trial for depression.
Feb 13, 2026
Arcutis Biotherapeutics is scheduled to report fourth-quarter and full-year 2025 results on Feb. 25, after market close. Investors will focus on sales performance of Zoryve and pipeline updates.
